ex-vivo allogeneic induced pluripotent stem cell-derived NK-cell based gene therapy (Editas Medicine/Blue Rock)

N/A

Report date: 2025/03/20 15:59:59

Base Information

Drug Nameex-vivo allogeneic induced pluripotent stem cell-derived NK-cell based gene therapy (Editas Medicine/Blue Rock)
Drug Alias Nameex vivo CRISPR/Cas12a allogeneic iPS NK-cell based gene therapy (Editas Medicine)iPSC-derived NK-cell therapy (Editas Medicine/Blue Rock)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunostimulantsNatural killer cells stimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEditas Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine IncBluerock Therapeutics Lp
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A